Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Alkylating agents leukemia

Hodgkin s disease lymphomas Alkylating agent leukemia lymphomas vasculitis... [Pg.152]

Alkylating agents Cyclophosphamide Myelosuppression, hemorrhagic cystitis Alopecia, stomatitis, amenorrhea, aspermia, secondary leukemias... [Pg.1313]

Streptozocin -alkylating agent cell cycle independent -nephrotoxicity—can be dose-limiting -nausea and vomiting—may get progressively worse with continued administration -mucocutaneous effects (mucositis, stomatitis, diarrhea) -bone marrow suppression -irritant if extravasated (not vesicant) -delirium or depression -risk of secondary leukemias... [Pg.178]

The alkylating agents can be considered to be cell-cycle independent drugs. They are used for the management of leukemias, lymphomas, multiple myeloma and some carcinoma s and soft tissue tumors, generally as components of drug combination regimens. Cyclophosphamide is also used for its marked immunosuppressant properties. [Pg.449]

The drug is highly active in the treatment of chronic lymphocytic leukemia, with approximately 40% of patients achieving remissions after previous therapy with alkylating agents has failed. Activity is also seen in the low-grade lymphomas. [Pg.645]

B. Indications and nse Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Determination of the effectiveness of Campath is based on overall response rates. Comparative randomized trials demonstrating increased survival or clinical benefits such as improvement in disease-related symptoms have not yet been conducted. [Pg.299]

Treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy... [Pg.469]

There is an increased risk of secondary cancers in the form of acute leukemia, and the carcinogenic potential of procarbazine is thought to be higher than that of most other alkylating agents. [Pg.1169]

NK cells, monocytes, macrophages, and a small population of granulocytes. Currently, alemtuzumab is approved for the treatment of -cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and have failed fludarabine therapy. Alemtuzumab appears to deplete leukemic and normal cells by direct antibody-dependent lysis. Patients receiving this antibody become lymphopenic and may also become neutropenic, anemic, and thrombocytopenic. As a result patients should be closely monitored for opportunistic infections and hematologic toxicity. [Pg.1197]

The alkyl sulfonate busulfan (Myleran) is metabolized to an alkylating agent. Because it produces selective myelosuppression, it is used in cases of chronic myelocytic leukemia. It causes pronounced hyperuricemia stemming from the catabolism of purine. [Pg.112]

See other pages where Alkylating agents leukemia is mentioned: [Pg.546]    [Pg.546]    [Pg.55]    [Pg.150]    [Pg.154]    [Pg.1290]    [Pg.1299]    [Pg.1382]    [Pg.1411]    [Pg.1411]    [Pg.512]    [Pg.722]    [Pg.292]    [Pg.546]    [Pg.4]    [Pg.399]    [Pg.108]    [Pg.121]    [Pg.123]    [Pg.213]    [Pg.215]    [Pg.302]    [Pg.449]    [Pg.722]    [Pg.157]    [Pg.169]    [Pg.1165]    [Pg.1166]    [Pg.1169]    [Pg.108]    [Pg.121]    [Pg.123]    [Pg.215]    [Pg.302]    [Pg.569]    [Pg.1282]    [Pg.1287]    [Pg.1312]    [Pg.1322]   
See also in sourсe #XX -- [ Pg.707 ]



SEARCH



Alkylating agents acute leukemia with

Alkylating agents alkylation

Alkylation agents

© 2024 chempedia.info